A spinal cord injury damages the nerve pathways between the brain and body, which can cause loss of movement, feeling, and bladder, bowel and sexual function below the injury. Nerve cells in the spinal cord do not regrow well, so researchers are testing whether stem cells can protect surviving tissue, reduce scarring or help rebuild connections.
AT A GLANCE · SPINAL CORD INJURY
| Evidence level | Early research |
|---|---|
| Approved stem cell treatment? | In December 2018 Japan granted conditional, time-limited approval to an autologous bone-marrow-derived mesenchymal stem cell product for spinal cord injury, based on an unblinded study of only 13 patients with no placebo group; scientists criticised the decision as premature and the product must still prove its benefit. |
| Typical private price | $20,000 – $140,000 (indicative) |
| Recruiting trials | 8 listed on ClinicalTrials.gov (4 October 2026) |
| Last reviewed | October 2026 |
Does stem cell therapy work for spinal cord injury?
Most human studies are small, early-phase and often uncontrolled, using bone marrow or umbilical cord mesenchymal stromal cells, neural stem cells or other cell types. A 2021 systematic review and meta-analysis in Cytotherapy pooled 19 studies with about 670 people with traumatic injury and found modest improvements in sensory scores, overall impairment grade and bladder function with mesenchymal cells, but no clear gains in motor scores or everyday activities.
Many included studies had no proper control group and used different doses, timings and injection routes, which makes the results hard to trust. Spontaneous recovery is common in the first year after injury, so uncontrolled reports can easily overstate benefit. Early trials of neural stem cells and embryonic-stem-cell-derived cells have mainly shown that the procedures can be done with acceptable safety, not that they restore function. Large, well-designed randomised trials showing meaningful recovery of walking or hand use are still missing.
Is any stem cell treatment approved for spinal cord injury?
In December 2018 Japan granted conditional, time-limited approval to an autologous bone-marrow-derived mesenchymal stem cell product for spinal cord injury, based on an unblinded study of only 13 patients with no placebo group; scientists criticised the decision as premature and the product must still prove its benefit. No stem cell product is approved for spinal cord injury by the US FDA or the European EMA. Elsewhere, stem cell treatments for spinal cord injury are offered only in clinical trials or as unapproved procedures.
What private clinics offer — and how it compares
Private clinics in several countries sell IV, spinal or direct-injection stem cell packages and show videos of patients who say they regained sensation or movement. These stories rarely account for natural recovery or intensive rehab done at the same time, and controlled trials have not shown that stem cells restore walking.
Proven treatments to discuss first
Before paying for an experimental option, make sure you have explored the established treatments for spinal cord injury with your doctor:
- Emergency surgery to decompress and stabilise the spine, ideally in a specialist centre
- Specialist inpatient and ongoing rehabilitation (physiotherapy, occupational therapy, activity-based therapy)
- Bladder, bowel, skin and breathing management to prevent complications
- Medicines and therapy for spasticity and nerve pain
- Spinal cord stimulation approaches (implanted or non-invasive) combined with rehab, in trials or approved settings
- Assistive technology, wheelchairs, braces and home adaptations
How much does stem cell therapy for spinal cord injury cost?
Private clinics typically quote $20,000 to $140,000. Japan’s conditionally approved product was reported to cost about $140,000, mostly covered by Japanese national health insurance. Unregulated overseas packages vary widely and commonly run into the tens of thousands of dollars before travel and care costs; figures here are approximate. Compare prices by country in our cost guide and location guides, and check insurance coverage.
Risks and side effects
- Infection, meningitis or bleeding from spinal or direct cord injections
- Worsening pain, spasticity or new neurological symptoms
- Abnormal tissue growth or tumour-like masses reported after unregulated spinal cell injections
- Blood clots and other complications from travel and procedures in people with limited mobility
- High costs and lost time away from proven rehabilitation
Recruiting clinical trials for spinal cord injury
On 4 October 2026, ClinicalTrials.gov listed 8 recruiting or soon-to-recruit stem cell studies for this condition, 2 with sites in the United States. Here are up to eight, latest-stage first:
See all matching studies on ClinicalTrials.gov. A listing is not an endorsement: registration does not mean a study is safe or effective, and genuine trials rarely charge you for the experimental treatment. Ask the study team about costs, placebo groups and follow-up before you enrol. See our clinical trials hub.
Questions to ask before you agree to treatment
- How do you separate the effect of the cells from natural recovery and rehabilitation in your results?
- Where are your outcomes published, and how many patients had a complete versus incomplete injury?
- How will the cells be delivered (IV, lumbar puncture, or directly into the cord), and what are the complication rates?
- Is this a registered trial, and what follow-up care is provided once I return home?
Before You Pay: The Stem Cell Clinic Checklist
- 20 questions every legitimate clinic should answer in writing
- A red-flag scorecard to spot unregulated marketing
- Realistic 2026 cost ranges: US, Mexico, Panama & Europe
- How to find a registered clinical trial
Red flags to watch for
- Claims that stem cells will let a person with a complete injury walk again
- Results shown only as videos or testimonials, with no published controlled data
- Advice to stop or skip rehabilitation because the cells will do the work
Stem cell therapy for spinal cord injury: FAQs
Does stem cell therapy work for spinal cord injury?
Not reliably yet. Pooled studies show some small improvements in sensation and bladder function, but no clear gains in movement or daily activities, and many studies lacked control groups. Better trials are needed.
Is stem cell therapy approved for spinal cord injury?
Japan gave a conditional, time-limited approval in 2018 to one autologous bone marrow stem cell product, based on a small uncontrolled study, and it still has to confirm benefit. No stem cell product is approved for spinal cord injury by the US FDA or the European EMA.
How much does stem cell therapy for spinal cord injury cost?
The Japanese conditionally approved product was reported at about $140,000, largely covered by national insurance there. Private overseas clinics often charge tens of thousands of dollars, plus travel and care costs.
Can stem cells help me walk again after a spinal cord injury?
No controlled trial has shown that stem cells restore walking. Some improvement after injury happens naturally, especially in the first year and with intensive rehabilitation, which can make clinic results look better than they are.
Is stem cell therapy for spinal cord injury covered by insurance?
Outside Japan’s national system for its conditionally approved product, it is generally not covered. Rehabilitation, equipment and complication care are usually the parts insurance supports.
Related guides
- Stem cell therapy for autism
- Stem cell therapy for multiple sclerosis
- Stem cell therapy for ALS
- Stem cell therapy for stroke
- All conditions · Types of stem cell treatment · Clinical trials hub
Sources
- Current evidence on mesenchymal stem cell therapy for traumatic spinal cord injury: systematic review and meta-analysis (Cytotherapy, 2021)
- A new Japanese stem cell treatment raises hopes and ethical questions (InSight+, MJA)
- Japan’s approval of stem-cell treatment for spinal-cord injury concerns scientists (Nature, via ResearchGate)
- Stem cell therapy for spinal cord injury: lessons from Japan’s experiment in regulatory deregulation (PubMed)
- Efficacy of mesenchymal and embryonic stem cell therapy for spinal cord injury: systematic review and meta-analysis of human studies (Global Spine Journal, 2025)
- International stem cell tourism: a critical literature review and evidence-based recommendations
- FDA: Patient and consumer warning about potential serious risks of harm following use of unapproved products from human cells or tissues
Last reviewed October 2026. For general information only — not medical advice. We do not endorse any clinic or product. Always consult a qualified, licensed healthcare professional. See our medical disclaimer and editorial policy.